Related Experiment Videos
Schwann cell degeneration induced by doxorubicin (adriamycin)
J D England1, E K Rhee, G Said
1Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia 19104.
Abstract:
Doxorubicin is an anthracycline antineoplastic antibiotic that acts at the cell nucleus by intercalating between base pairs of DNA, thus inhibiting DNA-directed mRNA synthesis. Intraneural micro-injection of 0.19-0.38 micrograms of this substance into rat sciatic nerve results in a delayed subacute demyelination that is secondary to focal Schwann cell degeneration. Remyelination eventually occurs but is not complete until at least days 60-75 postinjection. Toxic Schwann cell disorders produced by agents such as doxorubicin may serve as useful models in understanding the pathogenesis of human demyelinative neuropathies.
Insights
Doxorubicin causes demyelination in rat sciatic nerves by damaging Schwann cells. While remyelination occurs, it is incomplete, offering insights into human demyelinative neuropathies.
Area of Science:
- Neuroscience
- Toxicology
- Cell Biology
Background:
- Doxorubicin is an anthracycline antibiotic used in chemotherapy.
- It functions by intercalating into DNA and inhibiting mRNA synthesis.
- Schwann cells are crucial for nerve myelination.
Purpose of the Study:
- To investigate the effects of doxorubicin on nerve structure.
- To model toxic Schwann cell disorders and demyelinating neuropathies.
Main Methods:
- Intraneural micro-injection of doxorubicin into rat sciatic nerves.
- Observation of histological changes and demyelination.
- Assessment of Schwann cell degeneration and remyelination.
Main Results:
- Doxorubicin induced delayed subacute demyelination secondary to focal Schwann cell degeneration.
- Remyelination was observed but remained incomplete by day 75 post-injection.
Conclusions:
- Doxorubicin-induced toxic Schwann cell damage serves as a model for human demyelinative neuropathies.
- Understanding this model aids in studying the pathogenesis of these conditions.